IFN-γ resistance is a major obstacle in cancer immunotherapy, offering protection against T cell cytotoxicity and ICBs, and allowing tumor cells to exploit IFN-γ signaling for survival advantage rather than succumb to antitumor immunity. This evidence concerns the gene IFNG and cancer.